You are here: Industry Insights > Bispecific

News List

The R&D of CD20/CD3 Bispecific Antibody in China Yefenghong/PharmaSources
March 01, 2023
Currently, the R&D of CD20/CD3 bispecific antibody is still in the early stage. In China, few CD20/CD3 bispecific antibodies have entered the clinical stage, among which GB261 from Genor Biopharma has a good progress.
Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million En-CPhI.CN
October 08, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology ...
Glenmark to launch trial in solid tumours for its CD38xCD3 bispecific antibody GBR 1342 expressbpd
November 10, 2018
The decision to expand clinical development of GBR 1342 was based on a recently completed ex vivo translational study in multiple solid tumours utilising the clinically validated CANscript platform, where treatment with GBR 1342 revealed predictive respon
ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks b3cnewswire
November 10, 2018
The project met the primary goals for the bispecific antibody cell line, which were achieving high titers and bispecific purity and maintaining stability during scale-up. Zymeworks is continuing further process development and large-scale production.
Bispecific antibody builder Abpro postpones $69M IPO fiercebiotech
May 16, 2018
The early-stage biotech Abpro has postponed its $69 million IPO, according to a report from Renaissance Capital, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year
Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies worldpharmanews
January 13, 2017
Amgen and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multi